ClinicalTrials.govpublic full text
Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS)
multiple sclerosis, multiple sclerosis, relapsing-remitting, daclizumab, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 805737
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.